ERS2 Antibody

What is ESR2 and why is it an important target for antibody research?

ESR2 (estrogen receptor beta) is a member of the nuclear receptor superfamily that can transduce extracellular signals into transcriptional responses. It binds estrogens with an affinity similar to estrogen receptor alpha (ESR1) and activates expression of reporter genes containing estrogen response elements (ERE). ESR2 is considered particularly significant in breast cancer research because it has been thought to have an opposite effect to ESR1. While ESR1 is a key biomarker in breast cancer that predicts response to anti-estrogen treatment, ESR2's role has been more controversial, with some research suggesting it should not be blocked but activated in breast cancer to improve survival . The receptor's accurate detection and targeting are crucial for developing effective therapies for hormone-dependent cancers.

What applications are ESR2 antibodies commonly used for in research settings?

ESR2 antibodies are utilized across multiple experimental applications in research laboratories. According to validation data, these antibodies are primarily employed in:

The antibodies show reactivity with human and mouse samples most commonly, with some also validated for rat samples . It's important to note that optimal dilutions may be sample-dependent and should be determined empirically for each experimental system.

What are the key considerations when selecting an ESR2 antibody for research?

When selecting an ESR2 antibody, researchers should consider several critical factors to ensure experimental validity:

First, verify the antibody's validation status through knockout/knockdown controls. This is particularly important given historical issues with ESR2 antibody specificity . Second, confirm the immunogen used to generate the antibody - those created using recombinant ESR2 fusion proteins with defined regions are generally more reliable. Third, check the antibody's reactivity with your species of interest (human, mouse, rat), as cross-reactivity varies between products. Fourth, review the molecular weight observed in Western blots (typically 50-60 kDa for ESR2) compared to the calculated weight of 59 kDa . Fifth, examine published literature using the specific antibody catalog number to assess its performance in applications similar to your planned experiments.

What are the recommended sample preparation methods for ESR2 antibody applications?

Sample preparation protocols vary by application but should be optimized to preserve ESR2 epitope integrity while reducing background noise:

For Western blotting, cells or tissues should be lysed in buffer containing protease inhibitors, with proteins separated on 7.5-10% SDS-PAGE gels. For immunohistochemistry, antigen retrieval is crucial - ESR2 detection typically requires EDTA-based pH 8.0 buffer or alternatively citrate buffer pH 6.0, with heating for 15 minutes . For immunofluorescence, fixation with 4% paraformaldehyde followed by permeabilization with 0.1-0.5% Triton X-100 is commonly employed. Regardless of application, inclusion of appropriate positive controls (such as MCF-7 or SKOV-3 cells) and negative controls (such as ESR2 knockout samples or isotype control antibodies) is essential for result interpretation.

How should researchers address the controversy regarding ESR2 antibody specificity in breast cancer research?

The specificity controversy surrounding ESR2 antibodies represents one of the most significant challenges in the field. Research published in Nature Communications revealed that all but one of the 13 commonly used antibodies for ESR2 detection were potentially invalidated, suggesting they mistook other proteins for ESR2 . This has profound implications for nearly two decades of breast cancer research focused on ESR2 as a therapeutic target.

To address this issue, researchers should:

• Re-evaluate historical findings using only antibodies that have passed rigorous validation via multiple methods, particularly through genetic knockdown/knockout controls.

• Employ orthogonal detection methods beyond antibody-based techniques, such as mass spectrometry or mRNA quantification.

• Validate antibody specificity in their specific experimental conditions using appropriate positive and negative controls.

• Consider implementing the "Antibody Validation by Systematic Comparisons" approach, comparing results from multiple antibodies targeting different epitopes of the same protein.

• Clearly document and report all validation steps in publications to improve research reproducibility.

This controversy underscores the critical importance of antibody validation and highlights how insufficiently validated reagents can potentially lead research efforts astray .

What is the significance of different epitope binding sites in ESR2 antibodies for experimental outcomes?

The epitope binding site of an ESR2 antibody significantly impacts experimental outcomes in multiple ways:

Different functional domains of ESR2 (DNA-binding domain, ligand-binding domain, etc.) may be differentially accessible depending on protein conformation, interaction partners, or post-translational modifications. For example, antibodies targeting the N-terminal region versus the C-terminal region may yield different results when ESR2 forms complexes with other proteins or chromatin.

A parallel can be drawn from research on ErbB2 antibodies, where targeting different domains produces distinct biological effects. The anti-ErbB2 antibody trastuzumab recognizes domain IV, while pertuzumab binds domain II, and the novel H2-18 antibody targets domain I . Each antibody demonstrates unique effects on downstream signaling pathways like MAPK/ERK and PI3K/AKT, despite targeting the same protein .

For ESR2, researchers should carefully consider:

• Whether the antibody's epitope is within a region involved in protein-protein interactions

• If the epitope might be masked by conformational changes upon ligand binding

• Whether the epitope is conserved across species if conducting comparative studies

• If the epitope is present in all known splice variants of ESR2

Understanding these factors is essential for proper experimental design and interpretation of results across different applications.

How do ESR2 antibodies perform in detecting various ESR2 isoforms, and what are the implications for research?

ESR2 exists in multiple isoforms (ESR2-1/β1, ESR2-2/β2, ESR2-3/β3, ESR2-4/β4, and ESR2-5/β5) due to alternative splicing of the last coding exon, resulting in proteins with unique C-terminal regions. This presents significant challenges for antibody-based detection and has important research implications:

Most commercially available ESR2 antibodies were developed against specific regions of the protein, and their ability to detect different isoforms varies considerably. Antibodies targeting the N-terminal region typically detect all isoforms, while those targeting the C-terminal region may only recognize specific variants . This variability creates challenges in data interpretation across studies using different antibodies.

Research implications include:

• Differential expression patterns: Isoform expression varies across tissues and disease states, with certain variants potentially having opposing functions.

• Therapeutic relevance: Different isoforms may respond differently to estrogen or anti-estrogen therapies, potentially explaining some treatment resistance mechanisms.

• Subcellular localization: Isoforms may localize to different cellular compartments, requiring careful interpretation of immunohistochemistry or immunofluorescence results.

For accurate research, scientists should:

• Clearly specify which isoform(s) their antibody detects

• Use isoform-specific primers for qPCR validation

• Employ antibodies with documented specificity for particular isoforms when studying isoform-specific functions

• Consider using recombinant expression systems to validate antibody detection of individual isoforms

What are the recommended approaches for validating ESR2 antibody specificity in light of recent controversies?

Given the significant issues identified with ESR2 antibody specificity in breast cancer research , a multi-layered validation approach is essential:

• Genetic Controls: Utilize CRISPR/Cas9 knockout or siRNA knockdown systems to create negative controls. This represents the gold standard for antibody validation.

• Orthogonal Validation: Compare antibody detection with non-antibody-based methods such as:

  • Mass spectrometry for protein detection

  • qRT-PCR for mRNA expression correlation

  • GFP-tagged ESR2 overexpression systems

• Cross-platform Validation: Test the antibody across multiple techniques (WB, IHC, IF, IP) to ensure consistent results. Discrepancies between applications may indicate specificity issues.

• Multiple Antibody Approach: Compare results using multiple antibodies targeting different epitopes of ESR2. Consistent results across antibodies increase confidence in specificity.

• Positive and Negative Tissue Controls: Include known ESR2-positive tissues (ovary, testis) and ESR2-negative or low-expressing tissues as experimental controls.

A comprehensive validation strategy significantly reduces the risk of building research on faulty reagents, which has been identified as a major issue leading to a potential "20-year dead end" in ESR2 breast cancer research .

How can researchers optimize ESR2 antibody-based immunohistochemistry protocols for improved sensitivity and specificity?

Optimizing immunohistochemistry (IHC) protocols for ESR2 detection requires careful attention to several parameters:

Antigen Retrieval Optimization:
ESR2 epitopes are particularly sensitive to fixation methods. EDTA-based buffers at pH 8.0 have shown superior results compared to citrate buffers for many ESR2 antibodies . Consider testing multiple retrieval conditions:

Blocking and Antibody Incubation:

• Use 5-10% normal serum from the species of the secondary antibody

• Optimize primary antibody concentration through titration (typically 1:50-1:500 dilutions)

• Consider extended incubation at 4°C overnight versus 1-2 hours at room temperature

• Evaluate different detection systems (ABC, polymer-based) for signal amplification

Signal Development and Counterstaining:

• Optimize DAB development time for ideal signal-to-noise ratio

• Consider using hematoxylin counterstaining of varying intensities

Validation Controls:

• Include positive controls (ovary tissue sections)

• Use negative controls (antibody diluent alone)

• Consider competition with immunizing peptide as specificity control

This optimization approach significantly improves the reliability of ESR2 detection in tissue samples and reduces the risk of false-positive or false-negative results that have complicated historical research.